ABSTRACT
Retinoblastoma is the most common intraocular malignancy in childhood. With the advanced management strategy, the global salvage and overall survival have significantly improved, which proposes subsequent challenges regarding long-term surveillance and offspring screening. Here, we developed deep learning algorithm, called Deep Learning Assistant for Retinoblastoma (DLA-RB) training on A total of 36623 images from 713 patients. We validated it in the prospectively collected dataset, comprised of 1366 images form 139 eyes of 103 patients. In identifying active retinoblastoma tumors (treatment required) from all clinical-suspected patients, the area under the receiver operating characteristic curve (AUC) of DLA-RB reached 0.991 (95% CI 0.970-1.000). In identifying active retinoblastoma from stable retinoblastoma patients (treatment is not required), AUC of DLA-RB reached 0.962 (95% CI 0.915-1.000), respectively. Cost-utility analysis revealed that DLA-RB based diagnosis mode is more cost-effective in both retinoblastoma diagnosis and retinoblastoma activity surveillance. The DLA-RB achieved high accuracy and sensitivity in identifying active retinoblastoma from the normal and stable retinoblastoma fundus. It can be incorporated within telemedicine programs in the future.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Beijing Hospitals Authority' Ascent Plan (DFL20190201); National Natural Science Foundation of China (82141128); The Capital Health Research and Development of Special (2020-1-2052); Science & Technology Project of Beijing Municipal Science & Technology Commission (Z201100005520045, Z181100001818003)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The methods were performed in accordance with relevant guidelines and regulations and approved by the Medical Ethics Committee of Beijing Tongren Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
